Last reviewed · How we verify

Cedilanid D — Competitive Intelligence Brief

Cedilanid D (DESLANOSIDE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: deslanoside. Area: Cardiovascular.

marketed deslanoside Sodium/potassium-transporting ATPase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Cedilanid D (DESLANOSIDE) — Novartis.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cedilanid D TARGET DESLANOSIDE Novartis marketed deslanoside Sodium/potassium-transporting ATPase 1982-01-01
Digicor DIGITOXIN Eli Lilly marketed digitoxin Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1 1982-01-01
Acylanid ACETYLDIGITOXIN Novartis marketed acetyldigitoxin Sodium/potassium-transporting ATPase 1975-01-01
Uabaina ouabain marketed ouabain Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (deslanoside class)

  1. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cedilanid D — Competitive Intelligence Brief. https://druglandscape.com/ci/deslanoside. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: